Worth reading
54Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
56
¥ millions (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFiscal year ended June 2021 (previous fiscal year) and fiscal year ending June 2022 (current-year forecast)8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales1,124 million yen+0.5%
Operating profit39 million yen
Ordinary income59 million yen
Net income58 million yen net income attributable to owners of the parent
Full-year earnings forecast
Net Sales
1,200 million yen
Operating profit
100 million yen
Ordinary income
100 million yen
Profit attributable to owners of the parent
100 million yen
Earnings per share
¥16.95
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Change in operating profit of the metabolomics business-34 million yen
- Change in operating profit of the biomarker business90 million yen
- Change in company-wide operating profit0 million yen
- Change in total operating profit56 million yen
New initiatives
- Expand and promote new analysis services
- Launch the healthcare solutions development business
- Research and development aimed at the early commercialization of mental health-related fields
- Create new businesses in the healthcare field
- Close HMT Europe by the end of 2021 and operate the European business through HMT America
Key KPIsA metric the company considers important as a management benchmark.
- Orders received in the metabolomics business996 million yenYear on year against the same period last year△15％
- Market share of the metabolomics businessApproximately 70%
- Number of metabolomics-related papers>9,000
- Number of papers in which the company was involved>600
- Cumulative number of tests>7,000
- Growth rate of the market for foods with function claims25.9 ％
Segment results
Metabolomics business
Net Sales
1,119 million yen
Operating profit
423 million yen
Biomarker business
Net Sales
4 million yen
Operating profit
-70 million yen
Corporate and eliminations
Operating profit
-313 million yen
Medium-term management plan targets
TargetThe advanced research and development support business is targeted to achieve average annual revenue growth of at least 7%, while the healthcare solutions business is targeted to generate recurring revenue and achieve segment profitability within approximately 5 years. Consolidated revenue of ¥1,600 million and consolidated net income of ¥200 million in fiscal 2025
Target fiscal yearFY2025
Market Size / Share
- Global contract metabolomics market¥193 billion 2020
- Global contract metabolomics market¥220 100 million 2025 forecast
- Global biomarker market¥4.3 trillion 2020
- Global biomarker market¥9.2 trillion 2025 forecast
- Japanese healthcare market¥12.5 trillion 2025 forecast
- The company's share of the contract metabolomics marketApproximately 70%
Orders received and order backlog
Orders received
¥996 million metabolomics business, fiscal year ended June 2021
Number of employees
Number of Employees75 People consolidated, as of June 2021
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Fiscal year ended June 2021 (previous fiscal year) and fiscal year ending June 2022 (current-year forecast) |
| Net Sales | 1,124 million yen (YoY +0.5%) |
| Operating profit | 39 million yen |
| Ordinary income | 59 million yen |
| Net income | 58 million yen (net income attributable to owners of the parent) |
| Full-year earnings forecast | Net Sales 1,200 million yen / Operating profit 100 million yen / Ordinary income 100 million yen / Profit attributable to owners of the parent 100 million yen / Earnings per share ¥16.95 |
| Segment results | Metabolomics business Net Sales 1,119 million yen / Operating profit 423 million yen / Biomarker business Net Sales 4 million yen / Operating profit -70 million yen / Corporate and eliminations Net Sales Not disclosed / Operating profit -313 million yen |
| Breakdown of Factors Affecting the Change | Factors Change in operating profit of the metabolomics business / Amount -34 million yen, Factors Change in operating profit of the biomarker business / Amount 90 million yen, Factors Change in company-wide operating profit / Amount 0 million yen, Factors Change in total operating profit / Amount 56 million yen |
| Key KPIs | Indicator name Orders received in the metabolomics business / Value 996 million yen / Year on year against the same period last year △15％, Indicator name Market share of the metabolomics business / Value Approximately 70% / Year on year against the same period last year Not disclosed, Indicator name Number of metabolomics-related papers / Value >9,000 / Year on year against the same period last year Not disclosed, Indicator name Number of papers in which the company was involved / Value >600 / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of tests / Value >7,000 / Year on year against the same period last year Not disclosed, Indicator name Growth rate of the market for foods with function claims / Value 25.9 ％ / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 75 People (consolidated, as of June 2021) / Change during the period Not disclosed / Hiring plan Not disclosed |
| Medium-term management plan targets | Target The advanced research and development support business is targeted to achieve average annual revenue growth of at least 7%, while the healthcare solutions business is targeted to generate recurring revenue and achieve segment profitability within approximately 5 years. Consolidated revenue of ¥1,600 million and consolidated net income of ¥200 million in fiscal 2025 / Target fiscal year FY2025 |
| Orders received and order backlog | Orders received ¥996 million (metabolomics business, fiscal year ended June 2021) / Order backlog Not disclosed |
| Market Size / Share | Market Global contract metabolomics market / Value ¥193 billion (2020), Market Global contract metabolomics market / Value ¥220 100 million (2025 forecast), Market Global biomarker market / Value ¥4.3 trillion (2020), Market Global biomarker market / Value ¥9.2 trillion (2025 forecast), Market Japanese healthcare market / Value ¥12.5 trillion (2025 forecast), Market The company's share of the contract metabolomics market / Value Approximately 70% |
| New initiatives | Expand and promote new analysis services, Launch the healthcare solutions development business, Research and development aimed at the early commercialization of mental health-related fields, Create new businesses in the healthcare field, Close HMT Europe by the end of 2021 and operate the European business through HMT America |
Items this document does not state (16)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company worked to expand orders in its metabolomics business, improve sales efficiency and reduce selling, general and administrative expenses. It also cited revenue growth in the academic and food sectors and expanded sales of new analysis services.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.